RADX

$4.86

Pre-MarketAs of Mar 17, 8:00 PM UTC

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.86
Potential Upside
5%
Whystock Fair Value$5.10
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops sever...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-92.10%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.00

Recent News

Simply Wall St.
Dec 22, 2025

Favourable Signals For Radiopharm Theranostics: Numerous Insiders Acquired Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Insider Monkey
Dec 15, 2025

Radiopharm (RADX) Sees Slight Pessimism From Analysts

We recently published 7 Best ASX Stocks to Buy Right Now. Radiopharm Theranostics Limited (NASDAQ:RADX) is one of the best ASX stocks. Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain metastasis and prostate cancer. B. Riley lowered its share price target for the firm to $13 from $15 and […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Dec 15, 2025

Top Midday Gainers

Radiopharm Theranostics (RADX) said Monday that interim data from its phase 2b clinical trial of RAD

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Oct 20, 2025

Radiopharm Theranostics Expects to Raise $22.7 Million Via Private Placement, Shares Down Pre-Bell

Radiopharm Theranostics (RADX) shares were down over 15% in recent Monday premarket activity after t

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
Oct 2, 2025

Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial

Radiopharm (RADX) Theranostics announced that it has received a positive recommendation from the Data Safety and Monitoring Committee to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the next dose level of 75mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2-positive advanced solid tumors. The DSMC is a multidisciplinary committee that conducts detailed reviews of study data, discusses potential safety events and provides reco

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.